2023-12-27 07:49:33 ET
DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- First Wave BioPharma, Inc. (NASDAQ: FWBI) stated, this morning, that it entered into a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD), which will enable First Wave BioPharma to focus its development resources on its three late-stage clinical programs: Capeserod, a selective 5-HT4 receptor partial agonist licensed from Sanofi; Adrulipase, a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency (EPI); and, after the closing of the recently announced potential business combination with ImmunogenX, Latiglutenase, a Phase 3-ready oral biotherapeutic for celiac disease.
First Wave BioPharma is trading at $6.55, up $2.86 (+77.99%), on 721.2K shares traded.
Its 52-week range is $2.75 to …
The post Listing Plans on Adding by Streamlining appeared first on 24/7 Market News .
For further details see:
Listing Plans on Adding by Streamlining
Disclaimer
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of First Wave BioPharma Inc. (FWBI) and does not buy, sell, or trade any shares of (FWBI). This article does not provide a professional analysis of a (FWBI) financial position. (FWBI) financial position and all other information regarding the featured Company should be verified directly with (FWBI). Please read our full disclaimer for more detailed information.
